Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312425 | 0.97 | ALDH1A1 (0.48) | S1PR1SELPALDH1A1MAPTTHRB | |
| SCHEMBL969822 | 0.97 | P2RY10 (0.44) | S1PR1P2RY10GPR34 | |
| SCHEMBL18262003 | 0.97 | P2RY10 (0.44) | S1PR1P2RY10GPR34 | |
| SCHEMBL7571747 | 0.97 | P2RY10 (0.44) | S1PR1P2RY10GPR34 | |
| SCHEMBL7573946 | 0.94 | FABP3 (0.42) | S1PR1SELPALDH1A1MAPTTHRB | |
| SCHEMBL19410782 | 0.91 | PLA2G2C (0.43) | P2RY10GPR34 | |
| SCHEMBL37519 | 0.91 | PLA2G2C (0.43) | P2RY10GPR34 | |
| SCHEMBL226745 | 0.91 | PLA2G2C (0.43) | P2RY10GPR34 | |
| SCHEMBL3963403 | 0.91 | PLA2G2C (0.43) | P2RY10GPR34 | |
| SCHEMBL17144721 | 0.91 | PLA2G2C (0.43) | P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0845981-B1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-09-25 | — | — | EP | claimed |
| US-5935936-A | A DRUG DELIVERY FOR GENE THERAPY COMPRISING A DIAMINO-POLY-ALKYLAMINE-CARBAMOYL CHOLESTEROL AND AT LEAST ONE PHOSPHATIDES | GENZYME CORPORATION (US) | 1999-08-10 | — | — | US | claimed |
| EP-0845981-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-06-10 | — | — | EP | claimed |
| WO-1997046223-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-12-11 | — | — | WO | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023092060-A1 | MICRORNA-DEPENDENT MRNA SWITCHES FOR TISSUE-SPECIFIC MRNA-BASED THERAPIES | CORNELL UNIVERSITY (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2021222304-A1 | SARS-COV-2 RNA VACCINES | MODERNATX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-0845981-B1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| US-5935936-A | A DRUG DELIVERY FOR GENE THERAPY COMPRISING A DIAMINO-POLY-ALKYLAMINE-CARBAMOYL CHOLESTEROL AND AT LEAST ONE PHOSPHATIDES | GENZYME CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0845981-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997046223-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |